Study on the Clinical Efficacy of Teclistamab
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
The aim of this study is to assess the clinical efficacy and safety of the anti-BCMA/CD3 bispecific antibody teclistamab (Tecvayli®) in a prospective, real-life setting in Belgium.
Eligibility criteria
Qualifiers
Age 18 years or older
Written informed consent
Has a diagnosis of relapsed and refractory multiple myeloma
Has already received at least three previous treatments
Disqualifiers
Has participated in a teclistamab trial (teclistamab or control arm) or teclistamab Single Patient Request (SPR) program
Has started teclistamab treatment >14 days before intended screening visit.
Trial design
Treatments tested in this trial
- Teclistamab
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
Janssen Pharmaceutica
Collaborator
Source ClinicalTrials.gov